8 August 2009

Researchers at test gammaglobulin immunotherapy

Experimental treatment might slow the rate of progression of Alzheimer’s disease
Mount Sinai School of Medicine: 26 June 2009
Researchers from Mount Sinai School of Medicine have begun testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is used to treat primary immunodeficiency disorders, but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.

Initial research in experimental models and patients suggests that immunotherapy targeting beta amyloid, the protein that forms the core of plaques in the brain, may provide a more effective way to treat AD. Antibodies that bind to beta amyloid are present in IGIV, which is made from the blood of several thousand healthy adults. This new effort seeks the public's participation in testing IGIV in a major clinical trial that is jointly funded by the National Institute on Aging and Baxter International, Inc. … > full press release : review by MedPage Today : comment from Alzheimer’s Society (UK)

Related information: Immune Globulin Intravenous (IgIV Study)

No comments:

Post a Comment

Alzheimer's Australia NSW

Alzheimer's Australia NSW
Alzheimer's Australia NSW

Latest headlines from Library News

Library News

Total Pageviews